Pikka Jokelainen

Dr. Pikka Jokelainen

Statens Serum Institut, Copenhagen, Denmark
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in Eurosurveillance
Verified
Journal Article
Open access
TJThor Bech Johannesen
Thor Bech Johannesen
CMCharlotte Munkstrup
Charlotte Munkstrup
SESofie Edslev
Sofie Edslev
SBSharmin Baig
Sharmin Baig
SNStine Nielsen
Stine Nielsen
MSMarc Stegger
Marc Stegger
A highly virulent sub-lineage of the Streptococcus pyogenes M1 clone has been rapidly expanding throughout Denmark since late 2022 and now accounts for 30% of the new invasive group A streptococcal infections. We aimed to investigate whether a shift in variant composition can account for the high incidence rates observed over winter 2022/23, or if these are better explained by the impact of COVID-19-related restrictions on population immunity and carriage of group A Streptococcus.

11 January 2024 in Eurosurveillance
Verified
Journal Article
Open access
ANAnne Christine Nordholm
Anne Christine Nordholm
BSBolette Søborg
Bolette Søborg
PJPikka Jokelainen
Pikka Jokelainen
KMKarina Lauenborg Møller
Karina Lauenborg Møller
LSLotte Flink Sørensen
Lotte Flink Sørensen
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
We report a surge of patients, especially children and adolescents, with respiratory disease caused byMycoplasma pneumoniaein Denmark since October 2023. While the surge has reached an epidemic level, no impact on hospital capacity has been observed; only 14% (446/3,195) of cases, primarily adults, required hospitalisation. Macrolide resistance was detected in less than 2% of samples tested. Timely monitoring of hospitalisations linked toM. pneumoniaeinfections has been established to inform the healthcare system, decisionmakers and the public.

1 October 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Hans-Peter FuehrerHans-Peter Fuehrer
Hans-Peter Fuehrer
Simone MorelliSimone Morelli
Simone Morelli
Maria UnterköflerMaria Unterköfler
Maria Unterköfler
ABAnna Bajer
Anna Bajer
KBKarin Bakran-Lebl
Karin Bakran-Lebl
Christina StrubeChristina Strube
Christina Strube
In the past few decades, the relevance of Dirofilaria immitis and Dirofilaria repens, causing cardiopulmonary and subcutaneous dirofilariosis in dogs and cats, and of Angiostrongylus vasorum, causing canine angiostrongylosis, has steadily increased in Central and Northern Europe. In this review, a summary of published articles and additional reports dealing with imported or autochthonous cases of these parasites is provided for Central (Austria, Czechia, Germany, Hungary, Luxemburg, Poland, Slovakia, Slovenia, and Switzerland) and Northern (Denmark, Finland, Iceland, Norway, and Sweden) Europe. Research efforts focusing on Dirofilaria spp. and A. vasorum have varied by country, and cross-border studies are few. The housing conditions of dogs, pet movements, the spread of competent vectors, and climate change are important factors in the spread of these nematodes. Dogs kept outside overnight are a major factor for the establishment of Dirofilaria spp. However, the establishment of invasive, diurnal, synanthropic, competent mosquito vectors such as Aedes albopictus may also influence the establishment of Dirofilaria spp. The drivers of the spread of A. vasorum remain not fully understood, but it seems to be influenced by habitats shared with wild canids, dog relocation, and possibly climatic changes; its pattern of spreading appears to be similar in different countries. Both Dirofilaria spp. and A. vasorum merit further monitoring and research focus in Europe.

21 July 2017 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
MLMinerva Laranjo-González
Minerva Laranjo-González
BDBrecht Devleesschauwer
Brecht Devleesschauwer
CTChiara Trevisan
Chiara Trevisan
AAAlberto Allepuz
Alberto Allepuz
Smaragda SotirakiSmaragda Sotiraki
Smaragda Sotiraki
VDVeronique Dermauw
Veronique Dermauw
Background Taenia solium and Taenia saginata are zoonotic parasites of public health importance. Data on their occurrence in humans and animals in western Europe are incomplete and fragmented. In this study, we aimed to update the current knowledge on the epidemiology of these parasites in this region. Methods We conducted a systematic review of scientific and grey literature published from 1990 to 2015 on the epidemiology of T. saginata and T. solium in humans and animals. Additionally, data about disease occurrence were actively sought by contacting local experts in the different countries. Results Taeniosis cases were found in twelve out of eighteen countries in western Europe. No cases were identified in Iceland, Ireland, Luxembourg, Norway, Sweden and Switzerland. For Denmark, Netherlands, Portugal, Slovenia, Spain and the UK, annual taeniosis cases were reported and the number of detected cases per year ranged between 1 and 114. Detected prevalences ranged from 0.05 to 0.27%, whereas estimated prevalences ranged from 0.02 to 0.67%. Most taeniosis cases were reported as Taenia spp. or T. saginata, although T. solium was reported in Denmark, France, Italy, Spain, Slovenia, Portugal and the UK. Human cysticercosis cases were reported in all western European countries except for Iceland, with the highest number originating from Portugal and Spain. Most human cysticercosis cases were suspected to have acquired the infection outside western Europe. Cases of T. solium in pigs were found in Austria and Portugal, but only the two cases from Portugal were confirmed with molecular methods. Germany, Spain and Slovenia reported porcine cysticercosis, but made no Taenia species distinction. Bovine cysticercosis was detected in all countries except for Iceland, with a prevalence based on meat inspection of 0.0002–7.82%. Conclusions Detection and reporting of taeniosis in western Europe should be improved. The existence of T. solium tapeworm carriers, of suspected autochthonous cases of human cysticercosis and the lack of confirmation of porcine cysticercosis cases deserve further attention. Suspected cases of T. solium in pigs should be confirmed by molecular methods. Both taeniosis and human cysticercosis should be notifiable and surveillance in animals should be improved.

30 April 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
ABAnna Bajer
Anna Bajer
ABAna Beck
Ana Beck
Relja BeckRelja Beck
Relja Beck
JBJerzy Behnke
Jerzy Behnke
DDDorota Dwużnik-Szarek
Dorota Dwużnik-Szarek
Julia WalochnikJulia Walochnik
Julia Walochnik
There is now considerable evidence that in Europe, babesiosis is an emerging infectious disease, with some of the causative species spreading as a consequence of the increasing range of their tick vector hosts. In this review, we summarize both the historic records and recent findings on the occurrence and incidence of babesiosis in 20 European countries located in southeastern Europe (Bosnia and Herzegovina, Croatia, and Serbia), central Europe (Austria, the Czech Republic, Germany, Hungary, Luxembourg, Poland, Slovakia, Slovenia, and Switzerland), and northern and northeastern Europe (Lithuania, Latvia, Estonia, Iceland, Denmark, Finland, Sweden, and Norway), identified in humans and selected species of domesticated animals (cats, dogs, horses, and cattle). Recorded cases of human babesiosis are still rare, but their number is expected to rise in the coming years. This is because of the widespread and longer seasonal activity of Ixodes ricinus as a result of climate change and because of the more extensive use of better molecular diagnostic methods. Bovine babesiosis has a re-emerging potential because of the likely loss of herd immunity, while canine babesiosis is rapidly expanding in central and northeastern Europe, its occurrence correlating with the rapid, successful expansion of the ornate dog tick (Dermacentor reticulatus) populations in Europe. Taken together, our analysis of the available reports shows clear evidence of an increasing annual incidence of babesiosis across Europe in both humans and animals that is changing in line with similar increases in the incidence of other tick-borne diseases. This situation is of major concern, and we recommend more extensive and frequent, standardized monitoring using a “One Health” approach.

7 September 2023 in Eurosurveillance
Verified
Journal Article
Open access
MRMorten Rasmussen
Morten Rasmussen
FMFrederik Trier Møller
Frederik Trier Møller
VGVithiagaran Gunalan
Vithiagaran Gunalan
SBSharmin Baig
Sharmin Baig
MBMarc Bennedbæk
Marc Bennedbæk
PJPikka Jokelainen
Pikka Jokelainen
We describe 10 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant BA.2.86 detected in Denmark, including molecular characteristics and results from wastewater surveillance that indicate that the variant is circulating in the country at a low level. This new variant with many spike gene mutations was classified as a variant under monitoring by the World Health Organization on 17 August 2023. Further global monitoring of COVID-19, BA.2.86 and other SARS-CoV-2 variants is highly warranted.